Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Leeds General Infirmary · The University of Texas MD Anderson Cancer Center · +4 more institutions
Abstract
This study investigated the efficacy, safety, and clinical benefit of alemtuzumab (Campath-1H) for patients with relapsed or refractory B-cell chronic lymphocytic leukemia exposed to alkylating agents and having failed fludarabine therapy. Ninety-three patients received alemtuzumab in 21 centers worldwide, with the aim to obtain an overall response rate of at least 20%. Dosage was increased gradually (target 30 mg, 3 times weekly, for a maximum of 12 weeks). Infection prophylaxis was mandatory, beginning on day 8, and continuing for a minimum of 2 months after treatment. Responses were assessed at weeks 4, 8, and 12, and patients were followed for 34 months. Overall objective response in the intent-to-treat…
Citation impact
- FWCI
- 34.79
- Percentile
- 100%
- References
- 28
Authors
11- MJMichael J. KeatingCorresponding
Leeds General Infirmary, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Texas Oncology, Millennium Engineering and Integration (United States), The Ohio State University
- IWIan W. Flinn
Leeds General Infirmary, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Texas Oncology, Millennium Engineering and Integration (United States), The Ohio State University
- VJVinay Jain
Leeds General Infirmary, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Texas Oncology, Millennium Engineering and Integration (United States), The Ohio State University
- JBJacques‐Louis Binet
Leeds General Infirmary, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Texas Oncology, Millennium Engineering and Integration (United States), The Ohio State University
- PHPeter Hillmen
Leeds General Infirmary, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Texas Oncology, Millennium Engineering and Integration (United States), The Ohio State University
Topics & keywords
- Alemtuzumab
- Medicine
- Fludarabine
- Internal medicine
- Adverse effect
- Surgery
- Refractory (planetary science)
- Population
- Good health and well-being